Global reach FDNA’s AI-powered genomic and phenotypic analysis platform is used by 70% of the world’s clinical geneticists across 10,000 sites in more than 130 countries, presenting a compelling opportunity to partner with large hospital networks, academic centers, and global labs to expand adoption and integration.

Rare disease focus With an extensive database of phenotypic and genotypic information for thousands of rare conditions, FDNA can be positioned to enhance diagnostic accuracy and speed for undiagnosed or complex genetic cases, appealing to specialty clinics and diagnostics labs seeking differentiation.

Collaborative potential Past partnerships with ThinkGenetic, Ambry Genetics, and Guardian Research Network indicate a market-ready willingness to co-develop precision medicine workflows; target by proposing joint go-to-market, data collaborations, and integrated decision-support solutions.

Cost and value FDNA’s technology promises faster decision support and improved patient outcomes, which can translate into cost savings and shorter diagnostic journeys for health systems; align sales discussions with ROI, patient flow efficiency, and value-based care opportunities.

Mid-market sweet spot Current revenue range and company size suggest a focus on mid-market hospitals, genetics labs, and regional health networks where scalable AI phenotyping can be deployed rapidly, complemented by training and support services to accelerate adoption.